Restricted accessResearch articleFirst published online 2020-07
Response to Okeke and Rai:“Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Center Prospective Nonrandomized Trial” by Gallioli et al.
GallioliA, BoissierR, TerritoA, et al.Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: A single-centre prospective non-randomized trial. J Endourol, 2020; 34:573–580.
2.
OkekeZ, RaiA. Editorial comment on Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: A single-centre prospective non-randomized trial (from Gallioli A et al. J Endourol 2020. doi: 10.1089/end.2019.0750.) J Endourol, 2020; 34:791–792.
3.
HolsteinAF, SandmannJ, BresselM, DavidoffMS. Reinvestigation of the transitional epithelium (urothelium) of the human ureter. Ann Anat, 1994; 176:109–117.
4.
CattoJWF, HartmannA, StoehrR, BoldersonE, RehmanI, RosarioDJ, HamdyFC, MeuthM. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol, 2006; 175:2323–2330.
